Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
International Journal of Particle Therapy|December 3, 2019
Incorporating NTCP into Randomized Trials of Proton Versus Photon TherapyJonas Scherman, Ane L Appelt, Jen Yu, et al.
JMIR Research Protocols|September 15, 2022
Individualizing the Oncological Treatment of Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma by Using Gene Sequencing and Patient-Reported Outcomes: Protocol for the INDIGO StudyIda Marie Lind Rasmussen, Anne Vest Soerensen, Anne Kirstine Møller, et al.
Acta Oncologica (Stockholm, Sweden)|September 16, 2025
Predictors of acute and late diarrhea in the treatment of anal cancer with concurrent chemoradiotherapyKatrine Smedegaard Storm, Karen-Lise Garm Spindler, Gitte Fredberg Persson, et al.
The British Journal of Radiology|July 6, 2018
Feasibility of a novel liquid fiducial marker for use in image guided radiotherapy of oesophageal cancerSteen Riisgaard de Blanck, Jonas Scherman-Rydhög, Mette Siemsen, et al.
Acta Oncologica (Stockholm, Sweden)|September 22, 2025
Dosimetric impact of esophageal motion in esophagus-sparing radiotherapy of spinal metastasesAnna Mann Nielsen, Laura Ann Rechner, Sebastian Moretto Krog, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 2, 2017
Target position uncertainty during visually guided deep-inspiration breath-hold radiotherapy in locally advanced lung cancerJonas Scherman Rydhög, Steen Riisgaard de Blanck, Mirjana Josipovic, et al.
BMJ Open|January 30, 2023
Randomised phase II trial of stereotactic body radiotherapy in combination with checkpoint inhibitors in metastatic castration-resistant prostate cancer (CheckPRO): a study protocolNicklas Juel Spindler, Gitte Fredberg Persson, Susann Theile, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 23, 2016
Liquid fiducial marker performance during radiotherapy of locally advanced non small cell lung cancerJonas Scherman Rydhög, Steen Riisgaard Mortensen, Klaus Richter Larsen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 25, 2024
Patient-reported outcomes after personalised dose-escalation for stage II-III non-small-cell lung cancer patients: Results from the randomised ARTFORCE PET-Boost trialSaskia A Cooke, José S A Belderbos, Bart Reymen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 18, 2018
The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial)Judi van Diessen, Dirk De Ruysscher, Jan-Jakob Sonke, et al.
Pageof 4